Carlos Telleria, PhDMcGill University Health Center Proteotoxic Stress Therapy in Ovarian Cancer The majority of ovarian cancers recur 18-24 months after first responding to chemotherapy. Residual cells hide out in the abdominal cavity and often become unresponsive to current chemotherapy when they grow back. Dr. Telleria researches therapies that would be administered chronically after chemotherapy […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
